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OBJECTIVOS: Analizar las actualizaciones hechas al cuadro Básico y Catálogo de
Medicamentos (CBM) del Sector Salud en el periodo 2006-2010. Analizar el grado de
apego al CBM en las compras de medicamentos realizadas por diferentes institu-
ciones del sector público de salud en el periodo 2006-2009. METODOLOGÍAS: Se
identificaron en el Diario Oficial de la Federación las actualizaciones (inclusiones,
modificaciones y exclusiones) realizadas al CBM en el periodo de 2006-2010. Se
analizó información de compra pública de medicamentos para el periodo 2006-
2009. Para el procesamiento de la información se construyó una base de datos con
la información en el programa estadístico Stata. RESULTADOS: En el periodo 2006-
2010 se han realizado 24 actualizaciones al CBM. En total se realizaron 359 cambios
de los cuales el 39% corresponden a inclusiones, 53% actualizaciones y un 8% a
exclusiones. El 78% de los cambios fueron realizados al Cuadro Básico de Insumos
para el primer nivel de atención y el 22% restante al Catálogo de Insumos para el
segundo y tercer nivel. Se identificó que aproximadamente sólo se compró el 80%
del total de medicamentos listados en el CBM además de que se identificaron
medicamentos cuyas presentaciones y/o sustancias activas no se encuentran lis-
tados en el CBM. CONCLUSIONES: La creación del CBM siguió tres objetivos funda-
mentales: promover la presentación uniforme para los medicamentos que adqui-
era el sector público; servir como instrumento de orientación para una prescripción
adecuada así como evitar la dispersión de criterios institucionales; y servir como
guía para la adquisición correcta de medicamentos. Los resultados encontrados
dan evidencia de que estos objetivos no se están cumpliendo por lo que es necesa-
rio reordenar y analizar el contenido y uso que se da al CBM en las instituciones del
sector público.
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OBJECTIVES: During 2009-2010 major health care reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the US,
AMNOG in Germany, HSPT in France, KVG in Switzerland and NHS proposed re-
form in the UK. These reforms have major implications on pricing, market access
and HEOR strategy for drug and device products. METHODS: To understand the
implications of these trends, we analyzed 2009-2010 reform bills and proposed
changes worldwide. Additionally, we interviewed public and private payers, key
opinion leaders and payer-influencers to understand implications of these reforms
on drug and device manufacturers. RESULTS: The global healthcare landscape is
expected to undergo significant change during 2011-2015. In the US, government
will play increased role as a single payer, especially with–Medicare, Medicaid and
CHIP programs– which will cover 114 million Americans, at a cost of $784 billion. In
Germany, AMNOG bill marked the end of free drug pricing and would lead to
increased insurance premiums (now 15.5% of wages). In the UK, NHS has proposed
to replace PCTs with 500-1000 GP-led consortia and use value-based pricing for
expensive drugs and devices. Overall, payers view that in the future, health eco-
nomic assessments would play critical role in pricing, coverage and reimburse-
ment of branded products. CONCLUSIONS: This analysis shows that global health-
care landscape is expected to undergo significant change during 2011-2015.
Discussions with payers, KOLs and payer-influencers highlights increased impor-
tance of HEOR data in the future.
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OBJECTIVES: Measuring the level of adherence to drugs is relevant to assess the
clinical benefits of prescribed treatments. Adherence can be defined as the extent
to which a patient intake of medicines coincides with the medical prescription. The
purpose of this study is to review the degree of adherence to drugs among Mexican
patients as part of the overall medical therapy. METHODS: A systematic review
was performed to retrieve information on quantity measures of drug adherence to
medical treatments in Mexico. Key words such as “treatment and patient adher-
ence,” “drug compliance” and “drug utilization” were searched in Pub Med, Med-
line, Embase, Medic Latina, and the Cochrane Library of Systematic Reviews from
1998 to 2010. RESULTS: Few published studies in Mexico quantify the extent of
adherence to drugs among Mexican patients. Most of these studies measured drug
adherence in three chronic diseases: diabetes, HIV/AIDS, and rheumatoid arthritis.
These were carried out at the regional level with patients from public health insti-
tutions. The main methods used were pill-count, questionnaires, and interviews
with patients. Adherence to diabetes medication reported frequencies in the range
of 17.2%- 54.2%, while in antiretroviral treatment for HIV/AIDS, the range was from
42% to 85.3%. One study reported adherence to disease-modifying antirheumatic
drugs in stable patients with early rheumatoid arthritis of 50.5%, with an increased
risk of non-adherence as the drug treatment scales-up. CONCLUSIONS: The range
of frequencies for drug adherence among diabetic and HIV/AIDS patients varies
widely. This can be attributed to the different methods used to measure adherence
and the lack of a standardized measuring technique. Adherence results are derived
from regional studies; therefore, further research is needed in order to obtain es-
timates with national representation. This is important for the design of drug
policies aimed at enhancing drug adherence to maximize the health benefits from
treatments.
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OBJETIVOS: O objetivo do presente estudo é identificar os principais preditores da
quantidade de medicamentos tomados por indivíduos com doenças crónicas, de
entre diferentes variáveis demográficas, de doença, personalidade, qualidade de
vida e psicossomáticos. MÉTODOS: Participantes são 603 indivíduos, com 41,19
anos de idade média, escolaridades média de 9,87 anos, 72,5% mulheres, portado-
res de uma das seguintes doenças crónicas: epilepsia, diabetes tipo 1 e 2, cancro,
miastenia gravis, esclerose múltipla, obesidade mórbida, com diagnóstico há mais
de três anos. As variáveis avaliadas foram, o número de medicamentos que o
indivíduo toma como variável dependente, e como variáveis independentes,
variáveis psicossociais, tais como, personalidade (neuroticismo e extroversão),
afecto positivo e negativo, componentes mental e físico do SF-36, sintomas psicos-
somáticos (dimensões, sistema nervoso, muscular e digestivo), variáveis demográ-
ficas (idade e escolaridade), e variáveis de doença (numero de anos de diagnóstico,
número de internamentos no último ano, percepção da gravidade da doença).
Recorreu-se à regressão linear hierárquica que incluía o número de medicamentos
tomados como variável dependente e como variáveis independentes, no primeiro
passo as variáveis demográficas, no segundo passo, as variáveis de doença, e no
terceiro as variáveis psicossociais. RESULTADOS: A solução explica 20,6% da
variância da variável dependente. Cada bloco acrescenta valores estatisticamente
significativos à solução. Os resultados sugerem que um quinto da variância na
quantidade de medicamentos tomados é explicada pelas variáveis psicossociais
em que, no modelo final, as variáveis demográficas e de doença são excluídas da
solução. Das variáveis independentes, os principais preditores são, o neuroticismo
(t5,62) os componentes físico e mental do SF-36, (t5,45, e t5,03) e o sistema
nervoso da variável psicossomática (t5,45) todos com um nível de significância
p0,0001.CONCLUSÕES:Um programa de intervenção que melhore a qualidade de
vida é passível de contribuir para a redução na tomada de medicação não essencial.
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OBJECTIVES: To evaluate expensive and broad-spectrum antimicrobials usage in
Songkhla hospital. METHODS: A prospective, chart review was performed on all
inpatients initiated with Levofloxacin, Meropenem, Imipenem/ Cilastatin, Pipera-
cillin/ Tazobactam and Cefoperazone/ Sulbactam from March to December 2010.
Pharmacist interventions were made when medication use evaluation (MUE) cri-
terias were not met and/or drug related problems (DRPs) were detected. RESULTS:
Overall, 347 patients received 412 courses with these antibiotics. Percentage of
empiric therapy was 80 % and specific therapy was 20 %. Pneumonia and sepsis/
septic shock were leading indications of these antibiotic uses. Cefoperazone/Sul-
bactam was the most frequently used. The appropriate use of Levofloxacin, Mero-
penem, Imipenem/Cilastatin, Piperacilin/Tazobactam and Cefoperazone/
Sulbactam was 46%, 40%, 46% 70% and 53% respectively. No indication and
incorrect drug dosage especially in patients with renal impairment were the most
common misuse of these antibiotics. Acceptance of interventions from physician
was 86% (25/29). The cost of inappropriate use of these antibiotics was 28,789 USD.
CONCLUSIONS: MUE program should be continuously performed for effective use
of antibacterial drug, safety and most benefit.
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OBJECTIVES: to describe the use of stimulants in a group of Mexican children with
ADHD in order to know some pharmacoepidemiological dataMETHODS:An obser-
vational and descriptive study in pediatrics patients based on a survey in a one year
period (June 2009 to June 2010) was done. Survey was answered by children parents
who signed an informed consent. Patients with diagnosis of ADHD and/or received
stimulant treatment with and without co-morbidity were considering. RESULTS:
Of 124 surveys, 85 were selected according to inclusion criteria. 61.2% of patients
received pharmacologic treatment; the drug most use among them was the stim-
ulant methylphenidate (94%). The mean age of stimulant users was 7.94 years (4-13
years), 81.2% were male, 76.5% were in a primary school and 94% had a non-
pharmacologic treatment. The average daily dose was 13.95mg. Immediate release
was the most prescribed form in three different commercial presentations, and 8%
received the long term release. Children with seven years old were who received
more methylphenidate prescription. The age and having a comorbidity increased
the probability (p0.005) for receiving methylphenidate treatment. The most fre-
quent side effect reported was loss of appetite.CONCLUSIONS:Methylphenidate in
an immediate action form was the most prescribed stimulant drug in seven years
old children with ADHD in the population studied. High percentage of children
received methylphenidate treatment.
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